|Day Low/High||109.40 / 110.47|
|52 Wk Low/High||58.59 / 109.75|
Traders can learn from watching, as well as doing, and with the FOMC meeting landing, now's best time to practice the former.
These stocks are priced for total imperfection. That's just what you want.
The stocks of many companies anticipated a more stringent series of tariffs and we didn't get them.
Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.
A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.
The aging population is creating a massive tailwind for companies that provide cutting-edge health care.
Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
These stocks and sectors are safe havens, and may even be opportunities.
Jounce Therapeutics and Ocular Therapeutix each provided investors with positive news morsels last week.
Here's the only way to explain why stocks jump like mad if the companies underneath them only perform slightly better than the analysts worried they would.
And as the semiconductor sector continues to shine, Brooks Automation is a name to keep in mind.
There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.
Watch the Russell 2000, housing activity, and mergers and acquisitions.
The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
Let's check out the charts of BMY.
These two firms have successful drugs and could make nice additions for larger companies.
This is the first time I can ever recall when a president is so attuned to the market that he will bend to its wishes.
RMPIA outperformed once gain during April.
Analyzing this year's stock draft contest and individual stock-picking vs. indexing.